Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan
San Diego, California--(Newsfile Corp. - July 21, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its plans to conduct a Phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School.The open-label Phase 2a clinical trial...
2021-07-21 7:00 AM EDT
Tryp Therapeutics to Host Q3 Investor Day on July 29, 2021
San Diego, California--(Newsfile Corp. - July 15, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will host their Q3 Investor Day on July 29, 2021 at 9:00 a.m. PDT.The event will include a presentation by Tryp's management team to discuss updates on its Psilocybin-for-Neuropsychiatric Disorders (PFNTM)...
2021-07-15 7:00 AM EDT
Tryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary Formulations
San Diego, California--(Newsfile Corp. - July 7, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB:TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program.Tryp's collaboration with the University of Michigan is part of a series of...
2021-07-07 7:00 AM EDT
Tryp Therapeutics to Present at the Psych Investor Summit
San Diego, California--(Newsfile Corp. - June 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Psych Investor Summit: Research & Development. The conference will be held virtually on July 7. Greg McKee, Chairman and CEO, will present information on the company and its drug development...
2021-06-24 7:00 AM EDT
Tryp Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
San Diego, California--(Newsfile Corp. - June 8, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the Ladenburg Thalmann Healthcare Conference. The conference will be held virtually on July 13 and 14. Greg McKee, Chairman and CEO; Jim Gilligan, President and Chief Science Officer; and Luke...
2021-06-08 7:00 AM EDT
Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference
San Diego, California--(Newsfile Corp. - June 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it is presenting at the "Psychedelics in Psychiatry and Beyond" conference sponsored by H.C. Wainwright & Co. The conference will be held virtually on June 17, 2021. Greg McKee, Chairman and CEO of Tryp, will provide...
2021-06-01 10:41 PM EDT
Tryp Therapeutics Partners with Alcami for Proprietary Formulations
San Diego, California--(Newsfile Corp. - May 25, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation ("Alcami"), a global pharmaceutical contract development and manufacturing organization (CDMO), to support the proprietary formulation of products for Tryp's...
2021-05-25 4:00 AM EDT
Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support
San Diego, California--(Newsfile Corp. - May 10, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Clinlogix, a Contract Research Organization (CRO), to support Tryp's clinical development of its Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program.Clinlogix has global experience with providing CRO services...
2021-05-10 4:00 AM EDT
Tryp Therapeutics Partners with Fluence for Psychotherapy Design
San Diego, California--(Newsfile Corp. - May 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) ("Tryp") a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities.Fluence is led by researchers and psychotherapists with direct experience in psychedelic clinical trials and...
2021-05-03 4:00 AM EDT
Tryp Therapeutics Announces Q2 2021 Financial Results
San Diego, California--(Newsfile Corp. - April 29, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), today announced its interim financial results for the three and six month periods ended February 28, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.The...
2021-04-29 9:05 AM EDT
Tryp Therapeutics Reports on Key Milestones for 2021
San Diego, California--(Newsfile Corp. - April 20, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, reported today on the Company's significant progress since successfully completing its Initial Public Offering in December 2020.Tryp is advancing two drug development platforms: Psilocybin-for-Neuropsychiatric Disorders (PFNTM) targeting chronic pain...
2021-04-20 7:00 AM EDT
Tryp Therapeutics to Host Investor Day on April 22
San Diego, California--(Newsfile Corp. - April 15, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it will be hosting its quarterly Investor Day on Thursday, April 22 at 9:00 a.m. PDT.Tryp would like to invite all current shareholders and prospective investors to connect directly with Tryp's management team to discuss...
2021-04-15 7:00 AM EDT
Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility
San Diego, California--(Newsfile Corp. - April 5, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company") a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today it has initiated quoting activity on the OTCQB® Venture Market (the "OTCQB") and is eligible for settlement and transfer of its common shares in the United States with The Depository Trust Company ("DTC"). The Company's common shares are...
2021-04-05 12:38 PM EDT
Tryp Therapeutics Announces Amendment to Option Plan and Option Grant
San Diego, California--(Newsfile Corp. - April 1, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has amended the terms of its stock option plan (the "Plan") and granted stock options (the "Options") to a director of the Company.The Plan was amended to: (i) permit the cashless exercise of Options; and (ii) to increase the number of...
2021-04-01 9:48 PM EDT
Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer
San Diego, California--(Newsfile Corp. - April 1, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has appointed Greg McKee as its Chief Executive Officer. Mr. McKee will also continue in his responsibilities as Chairman of the Board of Directors of the Company.Mr. McKee has extensive experience leading publicly traded...
2021-04-01 7:00 AM EDT
Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics
La Jolla, California--(Newsfile Corp. - March 18, 2021) - Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today that it has submitted a provisional patent (US 63/161,070) to improve how psychedelics are administered across a broad range of indications.The provisional patent describes novel methods for the formulation, delivery, and dosing of psychedelics resulting in a potential reduction...
2021-03-18 5:00 AM EDT
Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer
La Jolla, California--(Newsfile Corp. - March 9, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that it has appointed Luke Hayes as its Chief Financial Officer.Mr. Hayes has been active in the life science industry for more than 20 years with experience in technology transfer, venture capital, and finance. He started...
2021-03-09 8:53 PM EST
Tryp Therapeutics Announces Application to List on OTCQB
La Jolla, California--(Newsfile Corp. - March 4, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today that it has submitted its application for a listing to the OTCQB® Venture Market ("OTCQB").The Financial Industry Regulatory Authority or FINRA has accepted the Company's Form 211, which qualifies the Company's shares to trade in the...
2021-03-04 10:00 AM EST
Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference
La Jolla, California--(Newsfile Corp. - February 24, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today the company has been invited to present at the Stifel GMP Healthcare Conference: Healthcare Psychedelics: Addressing the Global Mental Health Crisis.Commencing on March 11, 2021, the virtual conference will host a series of in-depth...
2021-02-24 7:00 AM EST
Tryp Therapeutics Completes $2 Million Strategic Financing
La Jolla, California--(Newsfile Corp. - February 17, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that effective February 16, 2021, it has closed its previously announced financing (see news release February 5, 2021) and issued 3,333,333 million units (the "Units") at a price of $0.60 per Unit, for proceeds of $2 million (the...
2021-02-17 5:38 PM EST